Clinical Trials Logo

Diabetic Macular Edema (DME) clinical trials

View clinical trials related to Diabetic Macular Edema (DME).

Filter by:

NCT ID: NCT02633852 Completed - Clinical trials for Diabetic Macular Edema (DME)

Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

Start date: May 24, 2016
Phase: Phase 4
Study type: Interventional

A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema - TADI Study

NCT ID: NCT02585401 Completed - Clinical trials for Age-related Macular Degeneration (AMD)

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Start date: February 18, 2016
Phase: N/A
Study type: Observational

The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

NCT ID: NCT02424019 Completed - Clinical trials for Diabetic Macular Edema (DME)

Phase 4 IOP Signals Associated With ILUVIEN®

PALADIN
Start date: May 6, 2015
Phase: Phase 4
Study type: Interventional

This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.

NCT ID: NCT02080091 Terminated - Clinical trials for Diabetic Macular Edema (DME)

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies

ILUMINATE
Start date: December 2013
Phase: N/A
Study type: Observational

This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.

NCT ID: NCT02050828 Completed - Clinical trials for Diabetic Macular Edema (DME)

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

TIME-2
Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of AKB-9778 administered as daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab for 3 months in patients with diabetic macular edema.

NCT ID: NCT01702441 Completed - Clinical trials for Diabetic Macular Edema (DME)

Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

Start date: September 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections daily for 28 days in patients with diabetic macular edema (DME).

NCT ID: NCT00936520 Terminated - Clinical trials for Diabetic Macular Edema (DME)

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.